Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4341-4350

  Socinski, Mark A ^a   Morris, David E ^a   Halle, Jan S ^a   Moore, Dominic T ^a   Hensing, Thomas A ^a   Limentani, Steven A ^a   Fraser, Robert ^a   Tynan, Maureen ^a   Mears, Andrea ^a   Rivera, M Patricia ^a   Detterbeck, Frank C ^a   Rosenman, Julian G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; IRINOTECAN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHUS STENOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGITIS; ESOPHAGUS STRICTURE; FEMALE; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 16544389343     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.022     Document Type: Article

References (46)

1. American Cancer Society: Cancer facts and figures: 2004. http://www.cancer.org
2. Hensing T, Halle J, Socinski MA: Chemoradiotherapy for stage IIIA,B non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, WB Saunders, 2001. pp 291-303
3. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
4. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
5. Curran D, Scott C, Langer C, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr)
6. Pierre F, Maurice P, Gilles R, et al: A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 20:312, 2001 (abstr 1246)
7. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer: A randomized phase II study. Proc Am Soc Clin Oncol 21:290a, 2002 (abstr)
8. Arriagada R, Le Chevalier T, Quoix E: ASTRO plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma-A randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20:1183-1190, 1991
9. Rosenman JG, Halle JS, Socinski MA, et al: High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348-356, 2002
10. Socinski MA, Rosenman J, Halle J, et al: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: A modified phase I/II trial. Cancer 92:1213-1223, 2001
11. Socinski MA, Halle JS, Morris DE, et al: Long-term results of aggressive combined modality therapy employing induction and concurrent carboplatin/paclitaxel with dose-escalated thoracic conformal radiation therapy. Lung Cancer 41:S239, 2003(suppl 2)
12. Bechtel J, Socinski MA, Halle JS, et al: Post-induction chemotherapy (CT) gross tumor volume (GTV) predicts survival in stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 22:640, 2003 (abstr)
13. Socinski MA, Sandler A, Miller L, et al: Phase I trial of the combination of irinotecan (CPT-11), paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 19:1078-7087, 2001
14. Socinski MA, Sandler A, Israel V, et al: Phase II trial of irinotecan, paclitaxel, and carboplatin in patients with previously untreated stage IIIB/IV non-small cell lung cancer. Cancer 95: 1520-1527, 2002
15. Calvert A, Newell D, Gumbrell L, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
16. World Health Organization: WHO Handbook for Reporting Results of Cancer treatment. WHO Offset Publication 48, Geneva, Switzerland, World Health Organization, 1979
17. Dillman R, Herndon J, Seagren S, et al: Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
18. Sause W, Kolesar P, Taylor S: Five-year results: Phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992. Proc Am Soc Clin Oncol 17:453a, 1998 (abstr)
19. Vokes EE, Herndon JE 2nd, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002
20. Perez CA, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer 50:1091-1099, 1982
21. Fossella FV, Zinner R, Komaki R, et al: Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:312a, 2001 (abstr)
22. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial-CHART Steering Committee. Lancet 350:161-165, 1997
23. Belani C, Wang W, Johnson D, et al.: Induction chemotherapy followed by standard thoracic radiotherapy (HART) for patients with unresectable stage III A and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 22:622, 2003 (abstr)
24. Russo S, Rosenman J: General aspects of radiotherapy for lung cancer, in Detterbeck FC, Rivera MP, Socinski MA, et al (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, WB Saunders, 2001, pp 148-161
25. Delbaldo C, Syz N, Michiels S, et al: Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small cell lung carcinoma (NSCLC): A meta-analysis of the literature. Proc Am Soc Clin Oncol 22:623, 2003 (abstr)
26. Roth JA, Atkinson EN, Fossella F: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 21:1-6, 1998
27. Rosell R, Gomez-Codina J, Camps J: Pre-resectional chemotherapy in stage IIIA non-small cell lung cancer: A 7-year assessment of a randomized controlled trial. Lung Cancer 26:7-14, 1999
28. 0), II, and IIIA non-small cell lung cancer. J Clin Oncol 20:247-253, 2002
29. Speiser BL, Spratling L: Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. Int J Radiat Oncol Biol Phys 25:589-597, 1993
30. Bedwinek J, Petty A, Bruton C, et al: The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 22:23-30, 1992
31. Alberto P, Mirimanoff RO, Mermillod B, et al: Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: Results of a phase I-II study by the GOTHA group-Group d'Oncologie Thoracique des Regions Alpines. Eur J Cancer 31A:342-348, 1995
32. Taulelle M, Chauvet B, Vincent P, et al: High dose rate endobronchial brachytherapy: Results and complications in 189 patients. Eur Respir J 11:162-168, 1998
33. Wurstbauer K, Deutschmann H, Kranzinger M, et al: Radiotherapy for lung cancer: Target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation. Int J Radiat Oncol Biol Phys 44:333-341, 1999
34. Maguire PD, Marks LB, Sibley GS, et al: 73.6 Gy and beyond: Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol 19:705-711, 2001
35. Sim S, Rosenzweig KE, Schindelheim R, et al: Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51:660-665, 2001
36. Hayman JA, Martel MK, Ten Haken RK, et al: Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol 19:127-136, 2001
37. Bradley JD, Graham MV, Winter KW, et al: Acute and late toxicity results of RTOG 9311: A dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57:5137-5138, 2003 (suppl 2)
38. Wu KL, Jiang GL, Liao Y, et al: Three-dimensional conformal radiation therapy for non-small-cell lung cancer: A phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 57:1336-1344, 2003
39. Marks LB, Garst J, Socinski M, et al: Carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N) followed by accelerated hyperfractionated conformal radiation therapy (R/T): Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. Proc Am Soc Clin Oncol 22:637, 2003 (abstr)
40. Belderbos JS, De Jaeger K, Heemsbergen WD, et al: First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 66:119-126, 2003
41. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003
42. Detterbeck F, Jones D, Parker LJ: Inthrathoracic staging, in Detterbeck FC, Rivera MP, Socinski MA, et al, (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, WB Saunders, 2001, pp 73-93
43. Albain K, Scott C, Rusch V, et al: Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 22:621, 2003 (abstr)
44. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992
45. Jeremic B, Shibamoto Y, Acimovic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study. J Clin Oncol 14: 1065-1070, 1996
46. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999